Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement

in European Journal of Endocrinology
Restricted access

24-hour access to this article

USD $30.00

Background

Patients with hypopituitarism have an increased mortality. The aim of this study was to investigate comorbidities including cerebral infarction, type 2 diabetes mellitus (T2DM) and malignant tumors in patients with non-functioning pituitary adenomas (NFPA) with and without growth hormone replacement therapy (GHRT).

Methods

Observational cohort study in patients with NFPA within the western region of Sweden. Subjects were identified through the National Patient Registry and followed between 1987 and 2014. Patient records were reviewed and standardized incidence ratios (SIRs) with 95% CIs for comorbidities were calculated.

Results

In total, 426 patients were included, 206 with GHRT and 219 without. Median (range) follow-up time for patients with and without GHRT was 12.2 (0–24) and 8.2 (0–27) years, respectively. Mean ± s.d. BMI was 28.5 ± 4.5 and 26.5 ± 4.4 for patients with and without GHRT, respectively (P < 0.001). Incidence of cerebral infarction was increased (SIR: 1.39; 95% CI: 1.03–1.84; P = 0.032), with no difference between patients with and without GHRT. SIR for T2DM in patients not receiving GHRT was increased (1.65; 1.06–2.46; P = 0.018), whereas the incidence in patients receiving GHRT was not (0.99; 0.55–1.63; P = 0.99). The incidence of malignant tumors was not increased, either in patients with or without GHRT.

Conclusion

The incidence of cerebral infarction is increased in patients with NFPA irrespective of GHRT. Patients without GHRT had an increased risk of T2DM, whereas patients with GHRT had a normal incidence of T2DM, despite having higher BMI. Incidence of malignant tumors was not increased. Thus, long-term GHRT seems to be safe regarding risk of comorbidities.

Downloadable materials

  • Supplementary Table 1. Characteristics of 25 patients with non-functioning pituitary adenoma and type 2 diabetes mellitus at start of the study.

 

Official journal of

European Society of Endocrinology

Sections

Figures

  • View in gallery

    Morbidity in patients with non-functioning pituitary adenomas presented as standardized incidence ratios with 95% CIs in the whole cohort (total), patients with growth hormone replacement therapy (GHRT) and without (non-GHRT).

  • View in gallery

    Morbidity in patients with non-functioning pituitary adenomas presented as standardized incidence ratios with 95% CIs, sub grouped according to glucocorticoid replacement (GC).

Index Card

PubMed

Google Scholar

Related Articles

Altmetrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 21 21 21
Full Text Views 648 648 124
PDF Downloads 152 152 30